Virios Therapeutics, Inc. Stock Price, News & Analysis

Virios Therapeutics (Nasdaq: VIRI) announced the expected release of top-line results for its Phase 2 clinical trial on Long-COVID in June 2023. This study evaluates the combination of valacyclovir and celecoxib for symptomatic improvements in patients with Long-COVID. Key outcomes include assessments of fatigue, sleep, attention, pain, and anxiety. Currently, over 600 million people worldwide have been infected with COVID-19, with 30% experiencing PASC symptoms. The research, backed by an unrestricted grant to the Bateman Horne Center, aims to address the effects of reactivated herpes viruses linked to Long-COVID.

Virios Therapeutics (Nasdaq: VIRI) has announced an end-of-Phase 2 meeting with the FDA set for mid-March 2023 to discuss advancing IMC-1 into Phase 3 development for fibromyalgia (FM). After favorable results from the FORTRESS Phase 2b study, the company will seek feedback on its Phase 3 program aimed at submitting a new drug application for IMC-1. Notable findings include significant pain reduction in 'new' FM patients and strong safety profiles. A program update is expected by the end of April 2023.

Virios Therapeutics (Nasdaq: VIRI) announced that CEO Greg Duncan will present at the Planet MicroCap Showcase from December 6-8, 2022. His presentation on December 7 at 10:00 am ET will focus on the Phase 2b FORTRESS study analyzing fibromyalgia treatments. This presentation will be accessible via webcast, with an archived version available later on the company's website. Virios is advancing antiviral therapies for chronic conditions like fibromyalgia and Long-COVID.

Virios Therapeutics (Nasdaq: VIRI) reports promising findings from the FORTRESS study, indicating significant pain reduction benefits for fibromyalgia patients new to research, while experienced patients showed no notable improvement. The company plans to request an FDA meeting to advance its lead candidate IMC-1 into Phase 3 trials. Financial results for Q3 2022 show a net loss of $2.6 million, down from $4.1 million in Q3 2021, with cash reserves of $9.8 million expected to sustain operations through 2023.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced that it will report its third quarter 2022 financial results on November 14, 2022, before market open. A management conference call will follow at 8:30 a.m. ET to discuss these results and provide updates. The company is focused on developing antiviral therapies for chronic diseases like fibromyalgia. Its lead candidate, IMC-1, has received fast track designation from the FDA.

Virios Therapeutics, Inc. (Nasdaq: VIRI) successfully closed its underwritten public offering of 10 million shares at $0.50 each, generating gross proceeds of $5 million. Proceeds will primarily fund the clinical development of its lead candidate, IMC-1, aimed at treating fibromyalgia and other chronic conditions. The company has also granted underwriters a 45-day option to purchase an additional 1.5 million shares. This offering utilizes a previously filed shelf registration statement with the SEC, reflecting the company's commitment to advancing novel antiviral therapies.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced the pricing of a public offering of 10 million shares of common stock at $0.50 per share, aiming for gross proceeds of $5 million. The offering includes a 45-day option for underwriters to purchase an additional 1.5 million shares. The proceeds will primarily support the clinical development of IMC-1 and general corporate purposes. The offering is expected to close on September 22, 2022. ThinkEquity is the sole book-running manager.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced its intention to offer shares of common stock in an underwritten public offering, with all shares sold by the Company. Proceeds will primarily support clinical development for IMC-1 and other corporate purposes. ThinkEquity is the sole book-running manager for this offering, which is dependent on market conditions. The offering follows a previously filed shelf registration statement with the SEC. The Company aims to advance antiviral therapies targeting chronic diseases, including fibromyalgia.

Virios Therapeutics (Nasdaq: VIRI) announced topline results from its FORTRESS study of IMC-1 for treating fibromyalgia (FM). While the primary efficacy endpoint was not met (p=0.302), a significant improvement was observed in patients enrolled during the second half of the trial (p=0.03), coinciding with the dominance of the Omicron variant. IMC-1 demonstrated good tolerability, with lower dropout rates due to adverse events compared to placebo. Further analysis of the data is underway to determine the next steps for IMC-1's development.